• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Alnylam closes $175M purchase of Merck subsidiary
Alnylam Pharmaceuticals has closed its $175 million acquisition of Sirna Therapeutics Inc., a subsidiary of Merck & Co., it said Thursday. In January, Cambridge-based Alnylam (Nasdaq: ALNY), which develops therapies based on RNA interference, entered into a stock and cash deal to buy Merck’s rights and interest of Sirna. The price was far less than the $1.1 billion Merck paid for Sirna in 2006 for the San Francisco-based biotech, which is also focused on RNAi drugs. It was a move some considered…
Source: bizjournals.com Health Care:Hospitals headlines - March 6, 2014 Category: Hospital Management Authors: Patricia Resende Source Type: research